Adaptive Biotechnologies Corporation (ADPT) Covered Calls
Adaptive Biotechnologies Corporation translates the genetics of the adaptive immune system into clinical products. Leveraging a proprietary immune medicine platform that combines high-throughput sequencing and AI, the company specializes in Minimal Residual Disease (MRD) testing and immune-driven drug discovery. Its flagship clonoSEQ test is the first FDA-cleared assay for MRD detection in various blood cancers.
You can sell covered calls on Adaptive Biotechnologies Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ADPT (prices last updated Fri 4:16 PM ET):
| Adaptive Biotechnologies Corporation (ADPT) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 12.79 | -0.61 | 12.40 | 13.35 | 3.3M | - | 2.1 |
| Covered Calls For Adaptive Biotechnologies Corporation (ADPT) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 12.5 | 0.00 | 13.35 | -6.4% | -292.0% | |
| May 15 | 12.5 | 0.10 | 13.25 | -5.7% | -57.8% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Adaptive Biotechnologies (ADPT) operates at the intersection of immunology and data science. Its primary revenue generator is the clonoSEQ diagnostic test, a highly sensitive liquid biopsy used to monitor Minimal Residual Disease (MRD) in patients with blood cancers. By early 2026, the company has successfully expanded its "Immune Medicine" segment, utilizing a massive TCR-antigen map developed with Microsoft to fuel drug discovery partnerships, such as its ongoing collaboration with Genentech for personalized cancer cell therapies.
Competitive Landscape
The diagnostic and precision medicine space is highly competitive, with ADPT facing rivals in the liquid biopsy and genetic sequencing markets. The company differentiates itself through its specialized focus on the adaptive immune system and its robust clinical evidence base, which has led to widespread inclusion in national oncology guidelines.
- Natera, Inc.: A leading competitor in cell-free DNA (cfDNA) testing and a primary peer in the oncology diagnostic market.
- 10x Genomics, Inc.: A primary competitor in the life sciences research space, focusing on single-cell analysis and spatial biology.
- Veracyte, Inc.: A leading genomic diagnostics company that competes for clinical adoption in cancer testing and monitoring.
- Guardant Health, Inc.: A major rival in the liquid biopsy market, particularly in the detection of solid tumors and MRD.
- Nuvalent, Inc.: A high-growth peer in the targeted oncology space that shares similar institutional investor interest.
Strategic Outlook and Innovation
Adaptive’s 2026 strategic outlook is characterized by a push toward company-wide profitability. Management is targeting 30%+ volume growth for clonoSEQ while expanding its blood-based testing into community medical centers. Innovation at ADPT includes the expansion of its T-Detect pipeline, which aims to diagnose infectious diseases and autoimmune disorders using a single blood draw, leveraging its database of over 85 billion immune receptors to create a new diagnostic standard.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | KWEB covered calls | 1. | TVTX covered calls | |
| 2. | SLV covered calls | 7. | TLT covered calls | 2. | VISN covered calls | |
| 3. | EEM covered calls | 8. | TSLA covered calls | 3. | CMPX covered calls | |
| 4. | SPY covered calls | 9. | HYG covered calls | 4. | AXTI covered calls | |
| 5. | QQQ covered calls | 10. | SOFI covered calls | 5. | AAOI covered calls | |
Want more examples? ADP Covered Calls | ADSK Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
